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I am privileged to edit this Research Topic, Transcriptional Regulation in Cancers and Metabolic
Diseases under the guidance of Dr. Carol Prives. We hereby thank Drs. Antonino Belfiore and Claire
Perks for giving us the opportunity of editing the Research Topic. Given the large number of recent
publications on transcriptional regulation, this Research Topic is timely needed. It covers many
research hotspots, including p53’s gain-of-functionmutation, p63’s role in epithelial cells, mitosis- or
senescence-related transcription, and cancer-specific exosome. Overall, this Research Topic reviews
and updates the current trends in transcriptional regulation.
TwoMini Reviews summarize the roles of heat shock proteins in transcriptional regulation (1, 2).
In the first Mini Review, Alexandrova and Marchenko focused on a heat shock protein HSF1 in
mutant p53 (mutp53)-mediated oncogenic activation. They highlighted a novel connection between
HSF1 and mutp53 and hypothesized that pharmaceutically disrupting HSF1-mutp53 cooperation
might be beneficial to cancer patients. In the second Mini Review, Khurana and Bhattacharyya
outlined mechanisms through which another heat shock protein HSP90 activates gene expression.
That is, HSP90 co-activates transcription factors, interacts with chromatin remodeling factors, and
evicts histones from certain gene promoters.
Three Reviews explain transcriptional regulation of fate-determining transcription factors or
cofactors (3–5). In the first Review, Yoh and Prywes illustrated the regulatory network that impinges
upon the key epithelial transcription factor p63. In the second Review, Yoo and colleagues focused
on a ubiquitin-fold modifier, UFM1 in breast cancer. In the third Review, Sun and colleagues
categorized lysine acetyltransferases in normal and abnormal development of blood cells. Notably,
Sun et al. reported current drug developments in lysine acetyltransferase inhibitors.
Two Original research articles evaluate transcriptional regulation in uveal melanoma and aging,
respectively (6, 7). In the first Original research article, Huffman, Carstens, and Martinez profiled
the expression levels of 48 human NRs across a panel of cell lines from uveal melanoma, cutaneous
melanoma and melanocytes. In addition, the NR-to-NR and NR-to-genome expression correlation
analyses identified RXRγ as a potential driver for melanoma-specific signaling, and ERRα as the
uveal-melanoma-specific NR. In the second Original research article, Ma and colleagues analyzed
microarray data of differentially expressed genes after the knockdown of the cellular senescence-
inhibited gene (CSIG). CSIG, originally identified by this research group, is critical in regulating
cell senescence, cell cycle progression, stress response, and tumor metastasis. In this article, they
discovered novel CSIG targets that correlate with senescence. Interestingly, they inferred that CSIG
regulates the stability of certain target-gene transcripts.
Nath and colleagues presented an interesting Review on mitotic proteins in cancer development
(8). As the authors pointed out, deregulated transcriptional regulation of mitotic genes are common
in cancers, yet mutations are rarely observed for mitotic genes. Cell cycle-related transcription
program is interesting and warrants further investigation.
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One Review and one Opinion article appraised the possible
use of exosome in early cancer diagnosis (9, 10). In the Review
article, Qin and colleagues summarized the recent progress on
the identification of miRNAs from tumor samples. They grouped
different miRNAs based on their location as the cytosolic, body-
fluid or exosomal miRNAs. The authors proposed exosomal miR-
NAs as diagnostic biomarkers for lung tumors. In addition, they
described the current methods for the isolation and detection of
these RNAs in the tumor samples. Moreover, the authors hypoth-
esized how miRNAs have been transported/released into body
fluids from the tumor cells. In accompanying Opinion article,
Oltra supported cancer-associated exosome in cancer diagnosis
and prognosis.
In the end of this Research Topic, Davis and colleagues pre-
sented a very interesting Review on Nanotetrac in treating can-
cers (11, 12). In many cancers, Thyroid hormones, T3 and T4
have pro-angiogenic effects, which might be mediated by αVβ3
integrin. Nanotetrac is a nanoparticulate preparation of a T4
substitute, tetrac. Nanotetrac blocks T4-triggered αVβ3-mediated
transcriptional regulation. Therefore, Nanotetrac might be useful
in treating cancers.
By compiling all these excellent manuscripts into one
Research Topic, we hope that our readers will find this
Research Topic enlightening. We owe our thanks to the staff of
Frontiers Endocrinology Office, for their work in the completion
of this Research Topic. We are particularly thankful to Davor
Vidic, Shaun Evans, Caroline Drage and Byron Bitanihirwe
for help in communicating with authors during initiation
and completion of the Research Topic. All authors in this
Research Topic have provided their broad perspectives on
transcriptional regulation, whose insightful thoughts will both
benefit the field and be appreciated by fellow researchers. We are
indebted to our reviewers/review editors for their contribution to
this work.
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